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Summary: A method was developed for the quantitation of six eumelanin-related indolic compounds in
urine. The procedure employs methane ionization of the hexafluoroisopropyl and/or pentafluoropropionyl
derivatives of 5,6-dihydroxyindole, 5-hydroxy-6-methoxyindole, 6-hydroxy-5-methoxyindole, 5-hydroxy-6-
methoxyindolyl-2-carboxylic acid, 6-hydroxy-5-methoxyindolyl-2-carboxylic acid and 5,6-dimethoxyindolyl-
2-carboxylic acid together with their deuterated analogues, and selected ion-monitoring. Deuterated analogues
are added äs internal Standards to enzymatically hydrolysed urine before diethyl ether extraction.
The method was used for monitoring urinary excretion in patients with malignant melanoma treated with
cytostatics. In several cases, a decrease of the excretion of the eumelanin-related substances was recorded
after the therapy. The usefulness of the individual indolic compounds for such follow-up studies is discussed.
Eumelanin-verwandte Indolverbindungen im Harn behandelter Melanompatienten
Zusammenfassung: Eine Methode zur quantitativen Bestimmung von sechs Eumelanin-verwandten Indolver-
bindungen im Harn wurde erstellt. Das Verfahren verwendet die Methan-Ionisierung der Hexafluorisopropyl-
und/oder Pentafluo ropionyl-Perivate von 5,6-Dihydroxyindol, 5-Hydroxy-6-methoxyindol, 6-Hydroxy-5-
methoxyindol, 5-Hydroxy^methoxyindolyl-2-carbonsäure, 6^Hydroxy-5-methoxyindolyl-2-carbonsäure und
5,6-Dimethoxyindölyl-2-earbonsäure gemeinsam mit ihren deuterierten Analogen und Selected Ion Monito-
ring. Deuterierte Analoge wurden als interne Standards vor der Extraktion mit Diethylether nach enzyma-
tischer Hydrolyse der Konjugate zum Harn zugefügt.
Die Methode wurde zur Überwachung der Ausscheidung der Verbindungen im Harn von cytostatisch
behandelten Patienten mit malignem Melanom eingesetzt. In mehreren Fällen wurde nach der Therapie ein
Abfall der Ausscheidung Eumelaiün-verwandter Substanzen festgestellt. Die Brauchbarkeit der Bestimmung
der einzelnen Indolverbindungen für solche Überwachungsstudien wird diskutiert.
*) Supported partly by the Koningin Wilhelmina Fonds (Netherlands Cancer Foundation) project No. 82-10 GUKC (S.P.)
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Introduction
A well known problem in the management of cancer
patients is the detection of the clinically occult
changes of the disease. Different chemical approaches
to these problems have been attempted, particularly
in those tumours that exhibit characteristic biochemi-
cal features. Since malignant melanocytes usually syn-
thesize melanin, it is not surprising that attention
has been paid to the intermediates of the melanin
synthesis and their determination in urine and serum
of melanoma patients.
The attempts to use the pheomelanin precursor 5-S-
cysteinyl-DOPA s a tumour marker for malignant
melanoma are well known (1-3). Much less is
known, however, about the possibility of employing
eumelanin precursors and their metabolites (eumel-









Two of them, namely 5-hydroxy-6-methoxyindolyl-2-
carboxylic acid and 6-hydroxy-5-methoxyindolyl-2-
carboxylic acid, were identified by Duchon & Matous
in 1967 (4), the others were described during the last
three years (5 — 7).
Gas chromatography was shown to be a useful tech-
nique, providing good Separation of the eumelanin-
related indolic compounds from urine of patients
with malignant melanoma (5, 8). It failed, however,
to detect the substances in urine samples of healthy
persons, owing to their low concentrations and peak
interferences with other compounds. Therefore a
more selective technique of detection has been
chosen.
In this paper we report our flrst experience with a
gas Chromatographie mass spectrometric method in
chemical ionization mode, which has been used for
follow-up of the urinary excretion of eumelanin-re-
lated indolic compounds in patients before, during
and after cytostatic treatment.
Materials and Methods
Chemicals
Pentafluoropropionic anhydride and 1,1,1,3,3,3-hexafluoroiso-
propanol were purchased from Pierce Chemical Co., Rockford,
IL, U.S. A., Helix pomatia juice was obtained from l'Industrie




boxylic acid s well s their deuterium labelled analogues were
prepared s described earlier (9). The compounds were stored
s diluted ethyl acetate Solutions at —40 °C under nitrogen,
and their actual concentrations were measured shortly before
their use by gas chromatography with a flattie^ionization detec-
tor.
All other chemicals were purchased from Merck, Darmstadt,
West Germany.
Patients and treatment
Brief descriptions of the individual cases of the melanoma
patients are given in the legends to the figures.
All the patients were treated according to the following five
day chemotherapeutic scheme:
days 1—4: (a) bleomycin 30 mg/day in a continuous intrave-
nous infusion
(b) dacarbazine 300 mg/m2 & day intravenously
day 5 (a) vindesine 3 mg/m2 in an eight-hour infusion
(b) actinomycin D 2 mg/m2 in a haif-hour infusion
To improve the alimentary conditions of the melanoma
patients, 8400 kJ/day (2000 kcai/day) in the form of Nutrison®
(Nutricia Holland) were given for 25 days, starting 10 days
before the cytostatic treatment.
Samples
Twenty four-hour specimens of urine were collected from mela-
noma patients and from healthy volunteers. Ten ml aliquots
were then stored without any preservation at — 20 °C until use.
Hydrolysis, extraction and derivatizatiom
To 2 ml of urine, 500 μΐ of 2.5 mol/1 sodiuiii acetate buffer pH
6.2 and 100 μΐ of Helix pomatia juice were added. The solution
was bubbled with nitrogen, the tubes tightly closed and placed
in a shaking water bath at 37 °C for 90 min. To each hydrolysed
urine sample, a mixture of home-made deuterium labelled in-
dolic substances (300 μΐ) was added, containing approximately
loOpmol 5,6-dihydroxyindole, 890 pmol 5-hydroxy-6-methoxy-
indole, 400 pmol 6-hydroxy-5-methoxyindole, 560 pmol 5-hy-
droxy-6-methoxyindolyl-2-carboxylic acid, 190 pmol 6-hydr-
oxy-5-methoxyindolyl-2-carboxylic acid and 60 pmol 5,6-di-
methoxyindolyl-2-carboxylic acid. The samples were saturated
with NaCl and extracted with 2 χ 4 ml of diethyl ether. Pooled
extracts were dried over anhydrous sodium sulphate and evap-
orated to dryness at 40 °C under a stream of nitrogen.
Derivatization was carried out by the addition of 50 μΐ of
hexafluoroisopropanol followed by 100 ul of pentafluoropro-
pionic anhydride. The tubes were then heated in a heating
block at 60 °C for 10 min. After evaporation under a stream
of nitrogen, the residue was dissolved in 20 μΐ of ethyl acetate
containing 5% of pentafluoropropionic anhydride.
Gas chromatography-mass spectrometry
Gas chromatography-mass spectrometry was perfonned on a
Varian 3700 gas Chromatograph interfaced to Varian ΜΑΤ
44 S mass spectrometer with an open-split coupling. Data were
recorded on a Varian ΜΑΤ SS 200 data System. The gas
Chromatograph contained a 25 m χ 0.25 mm (i. d.) glass capil-
lary cohimn coated with SE-54 (Franzen Analysen-Technik,
Bremen, West Germany). Injector temperature was set at
240 °C, interface temperature at 250 °C arid source temperature
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a t 200 °C. Helium flow rate was 1.8 ml/min and ionization
energy 180 eV. The oven temperature was programmed from
150 to 230 °C at 10 °C/min. The reagent gas (methane) pressure
was 600 μbar.
Quant i f icat ion
The concentration of the indolic compounds was obtained by
calculating the peak-area ratios of the respective "pseudomole-
cular" [M + 1]+ ions oflabelled and non-labelled compounds
and comparing them to those obtained from known ratios
plotted in calibration curves using linear regression analysis
(PFP = pentafluoropropionyl, HFIP = hexafluoroisopropyl
derivative, -d0, -d2, -d4, -d5 = number of deuterium atoms in
the molecuie).
The following ions were monitored:
ra/z 588 corresponding to the [M + 1]+ of 5,6-dihydroxyin-
dole(PFP)3-d0
m/z 590 corresponding to the [M + l ]+ of 5,6-dihydroxyin-
dole(PFP)3-d2
m/z 456 corresponding to the [M -h 1]+ of 5-hydroxy-6-me-
thoxyindole(PFP)2-d0 and 6-hydroxy-5-methoxyin-
dole(PFP)2-d0
m/z 460 corresponding to the [M + 1]+ of 5-hydroxy-6-me-
thoxyindole(PFP)2-d4 and 6-hydroxy-5-methoxyin-
dole(PFP)2-d4
m/z 504 corresponding to the [M -f 1]+ of 5-hydroxy-6-me-
thoxyindolyl-2-carboxylic acid(HFIP-PFP)-d0 and 6-
hydroxy-5-methoxyindolyl-2-carboxylic acid(HFI]P-
PFP)-d0
m/z 509 corresponding to the [M + 1]+ of 5-hydroxy-6-me-
thoxyindolyl-2-carboxylic acid(HFIP-PFP)-d5 and 6-
hydroxy-5-methoxyindolyl-2-carboxylic acid(HFIP-
PFP)-d5
m/z 372 corresponding to the [M + 1]+ of 5,6-dimethoxyin-
dolyl-2-carboxylic acid(HFIP)-d0
m/z 380 corresponding to the [M -h 1]+ of 5,6-dimethoxyin-
dolyl-2-carboxylic acid(HFIP)-d8
The position of deuterium atoms in the indole molecules was
described earlier (9).
Results
As shown in figure l, the method used gave a good
Separation of all eumelanin-related indolic com-
pounds, which could therefore be measured in a single
Chromatographie run. The concentration of each sub-
stance was calculated by using its own internal Stan-
dard and calibration curve. In the concentration
r nge of 0.25 —25 nmol/1, the coefficient of Variation
of the method was satisfactory (2.5 — 6.0%). How-
ever, when normal urine samples and those contain-
ing extreme concentrations of indoles were analysed,
the coefficient of Variation was found to be higher
than 10%. In the latter case, quality control could
be improved by prior dilution of urine. The recoveries
of individual indolic eumelanin-related compounds
added to urine samples before their processing were
in the r nge of 80 — 120%.
The excretion values of indolic eumelanin-related
compounds in four melanoma patients before, during
and after the therapy are shown in figures 2—5.
Discussion
Although the group of eumelanin-related indolic sub-,
stances consists of seven indolic compounds, it ap-
pears that not all of them are suitable for routine
laboratory determination. In general, the main eume-
lanin precursors, namely 5,6-dihydroxyindole and
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Fig. 1. Mass fragmentograms obtained from a derivatized extract of raelanotic urine to which deuterated internal Standards were
added.
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Fig. 2 a-c. The urinary excretion of six eumelanin-related compounds by patient K., a woman aged 59, admitted with diagnosis
subungual melanoma. Treatment: surgical. In August 1982, generalization of the process with high tumour bürden
(pulmonary metastases). The arrows indicate the däys of the treatment.
readily undergo oxidation and polymerization. Their
O-methylation and/or conjugation with sulphate or
glucuronate at least partly protect them against the
mentioned processes. However, our experience has
shown that 5,6-dihydroxyindolyl-2-carboxylic acid is
excreted in an unconjugated form and may therefore
initiate secondary formation of melanin in melanotic
urine during collection and storage. That is why the
measured concentration of this substance in urine
may not be related solely to its production rate, but
may also be dependent on other conditions, such äs
pH of the urine or the presence of oxidative or reduc-
tive substances. In other words, the instability of this
eumelanin precursor would make the Interpretation
of its concentration values unreliable. That was the
reason why 5,6-dihydroxyindolyl-2-carboxylic acid
was not included in our measurements.
Although 5,6-dihydroxyindole is reported to be ex-
creted äs a sulphate conjugate (10), and thus partially
protected against polymerization and oxidation, its
determination is accompanied by several structurally
related difficulties:
(a) the compound is partially oxidized and polyiner-
ized during the hydrolysis,
(b) a small difference in the inasses of the deuterated
(d2) and natural (d0) analog causes partial quantita-
tive overlap of measured ions and results in a non-
linear calibration curve, and
(c) the instability of deuterated and non-deuterated
5,6-dihydroxyindole during storage of the Standard
Solutions used for calibration arid Standard addition.
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Fig. 3 a—b. The urinary excretion of four eumelanin-related compounds by patient St., a woman aged 24, admitted with diagnosis
skin melanoma (shoulder -f- lymph. nodes). Treatment: surgical and immunotherapy. In April 1981, generalization




















Fig. 4a-b. The urinary excretion of four eumelanin-related compounds by patient Si., a man aged 38, admitted with diagnosis
skin melanoma (the back side of the trunk). Treatment: surgical. In February 1982, tumour progression with low
tumour bürden (pulmonary metastases). The arrows indicate the days of the treatment.
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Fig. 5a-b. The urinary excretion of four eumelanin-related compounds by patient S. H., a woman aged 42, admitted with
diagnosis skin melanoma (leg). Treatment: surgical. In April 1982, generalization of the disease with high tumöur
bürden (pulmonary metastases). The arrows indicate the days of the treatment.
In view of these problems, the determination of 5,6-
dihydroxyindole also does not seem to be suitable for
routine purposes.
The recently discovered 5,6-dimethoxyindolyl-2-car-
boxylic acid (7) was present in normal urine in very
low, sometimes undetectable amounts. Although this
substance is interesting from the biochemical point
of view, the small differences in its excretions in
normal and melanotic urine (see fig. 2) make its
determination less useful.
From the foregoing it can be seen that O-methylated
indoles are apparently more suitable metabolites for
routine measurements because of their relative stabil-
ity. As shown in the follow-up curves of Ihe mela-
noma patients, 5-hydroxy-6-methoxyindole consis-
tently exhibited the highest differences between pre-
and post-therapeutic stadia. It appears that this sub-
stance is the most sensitive indicator of increased




found to be excreted in a pathological ränge, pnly if
the excretion of the 5-hydroxy-6-methoxyindole was
extremely elevated. In other cases, their excretion
values were in the normal physiological ränge, so
that they have limited value for the detection of the
increased eumelanin production. Our measurements
also showed a similar excretion of both isomeric
acids, so it appears to be sufficient to measure only
one of them.
Some patients exhibited a decrease of 5-hydroxy-6-
methoxyindole with a temporal overshoot of isomeric
5-hydroxy-6-methoxy- and 6-hydroxy-5-methoxyind-
olyl-2-carboxylic acid excretion after the treatment
(see fig. 5). This fact raises the question of whether
carboxylic and non-^carboxylic eumelanin-related
compounds share the same mode of generation, cell
compartmentalization, and exeretion froni the organ-
ism. .Further investigations äimed at interpreting the
behaviour of each eumelanin-related nietabolite will
be necessary. v r
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Since the eumelanin-related substances are «pecific
inetabolites of melanocytes, it is obvious that their
excretion might be dependent on the amount of these
melanin-forming cells äs well äs on their metabolic,
namely melanogenic activity. That is why the decrease
of the excretion of the eumelanin-related indoles after
the treatment does not necessarily mean the reduction
of the tumour mass, but may only indicate metabolic
changes in the cellular metabolism of the melanocy-
tes. The long-term follow-up may show whether these
changes are transient or permanent, in other words,
whether the treatment was effective. Correlation with
clinical picture and repetitive measurements of the
eumelanin-related compounds are therefore advis-
able.
In some cases, the high tumour load is not accom-
panied by an increased excretion of the eumelanin-
related metabolites (see fig. 5). This dissapointing fact
can be explained by
(a) a low melanogenic activity of the tumour cells
and/or by
(b) the existence of an alternative mode of excretion
of the indolic metabolites (via bile).
A further investigation must be carried out to clarify
the real cause of this discrepancy and to shed more
light on the Statement, made by Eppinger äs early äs
1910 (11), that so-called melanogenuria appears only
after the development of liver metastases.
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